Evidence map›Paper›PMID 32547497›Full record

ArticleFrontiers in endocrinology2020

A Remarkable Response of Granulomatous Hypophysitis to Infliximab in a Patient With a Background of Crohn's Disease-A Case Report.

Bahar K Force, Tiphanie P Vogel, Dang M Nguyen, Kent A Heck, Sherly Sebastian, Mas Takashima, Daniel Yoshor, Susan L Samson

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Lactotroph PitNET/adenoma associated to granulomatous hypophysitis in a patient with Crohn's disease: A case report.Neuropathology : official journal of the Japanese Society of Neuropathology · 2023
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Bahar K ForceSection of Endocrinology, Diabetes and Metabolism, Department of Medicine, Baylor College of Medicine, Houston, TX, United States.
Tiphanie P VogelDivision of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, TX, United States.
Dang M NguyenGreater Houston Gastroenterology, Houston, TX, United States.
Kent A HeckDepartment of Pathology and Immunology, Baylor College of Medicine, Houston, TX, United States.
Sherly SebastianBaylor St. Luke's Pituitary Center, Houston, TX, United States.
Mas TakashimaHouston Methodist Hospital, Department of Otolaryngology, Houston, TX, United States.
Daniel YoshorBaylor St. Luke's Pituitary Center, Houston, TX, United States.
Susan L SamsonSection of Endocrinology, Diabetes and Metabolism, Department of Medicine, Baylor College of Medicine, Houston, TX, United States.
Baylor College of Medicine · USSt. Luke's Hospital · USMethodist Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAutoimmune HypophysitisCrohn DiseaseFemaleHumansImmunosuppressive AgentsInfliximabTreatment OutcomeTumor Necrosis Factor-alphaImmunosuppressive AgentsInfliximabTumor Necrosis Factor-alphaadalimumabanti-TNF-alphacase reportCrohn's diseasegranulomatous hypophysitisinflammatory bowel diseaseinfliximabpituitary

Identifiers

PMID32547497
PMCPMC7272571
OpenAlexW3029643528

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.